US stock · Healthcare sector · Biotechnology

Regeneron Pharmaceuticals, Inc.

REGN

NASDAQ

750.12

USD

+11.49

(+1.56%)

Pre Market

19.04P/E

17Forward P/E

0.78P/E to S&P500

82.296BMarket CAP

- -Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

1 Aug-7 Aug

Shares Short

5/15/23

1.21M

Short % of Float

1.31%

Short % of Shares Outs.

1.11%

% Held by Insiders

2.54%

% Held by Institutions

89.64%

Beta

0.22

PEG Ratio

6.34

52w. high/low

837.55/538.01

Avg. Daily Volume

0.57M

Return %

Stock

S&P 500

1 year

21.08

3.24

3 years

25.50

32.76

5 years

142.13

53.98

Scale: |

High

Low

25.25

12.62

24.97

11.81

33.94

20.45

79.90

32.32

188.95

56.01

319.83

154.16

437.64

262.97

605.93

393.00

532.91

325.35

543.55

340.09

416.49

281.89

442.00

271.37

664.64

328.13

686.62

441.00

779.00

538.01

837.55

668.00

Currency: USD

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Revenue per share

1.88

3.03

4.75

5.54

4.92

14.56

21.50

28.02

39.82

46.41

55.22

62.19

72.01

78.97

149.37

113.66

115.36

Earnings per share

(1.59)

(1.05)

(0.85)

(1.26)

(2.45)

7.92

4.33

3.46

6.17

8.55

11.27

22.65

19.38

32.65

75.05

40.51

39.04

FCF per share

(1.87)

(2.15)

(0.04)

(2.40)

(1.37)

4.51

4.19

6.49

9.33

9.88

17.04

18.54

18.35

60.68

34.43

31.73

26.17

Dividends per share

- -

CAPEX per share

0.53

1.23

1.25

0.69

0.54

1.65

3.40

6.74

4.97

2.60

3.60

3.98

5.63

5.13

(34.43)

15.10

13.76

Book Value per sh.

6.94

5.31

4.97

6.36

5.36

13.15

19.94

25.27

35.46

42.49

57.78

81.16

101.55

102.47

174.43

211.62

205.84

Comm.Shares outs.

101

103

105

106

108

109

108

107

Avg. annual P/E ratio

(13.1)

(18.2)

(20.7)

(20.8)

(21.3)

16.6

54.7

95.7

80.2

46.2

37.5

15.6

17.7

16.3

7.4

16.3

19.0

P/E to S&P500

(0.8)

(0.3)

(1.0)

(1.3)

1.1

3.2

5.3

4.0

2.1

1.6

0.6

0.7

0.4

0.2

0.8

Avg. annual div. yield

- -

Revenue (m)

125

238

379

459

446

1,378

2,105

2,820

4,104

4,860

5,872

6,711

7,863

8,497

16,072

12,173

12,370

Operating margin

(91.5)%

(37.7)%

(19.5)%

(21.2)%

(46.0)%

33.2%

36.1%

29.7%

30.5%

27.4%

35.4%

37.8%

28.1%

42.1%

55.7%

41.0%

35.2%

Depreciation (m)

105

145

148

210

236

286

341

789

Net profit (m)

(106)

(83)

(68)

(104)

(222)

750

424

348

636

896

1,199

2,444

2,116

3,513

8,075

4,338

4,183

Income tax rate

- -

(2.9)%

5.7%

- -

0.5%

(81.0)%

40.5%

55.1%

48.1%

32.7%

42.3%

4.3%

12.9%

7.8%

13.4%

10.7%

9.7%

Net profit margin

(84.5)%

(34.7)%

(17.9)%

(22.8)%

(49.7)%

54.4%

20.2%

12.3%

15.5%

18.4%

20.4%

36.4%

26.9%

41.3%

50.2%

35.6%

33.9%

Working capital (m)

514

438

332

249

505

1,042

1,498

1,513

2,104

1,939

3,200

5,005

5,593

7,082

10,082

12,743

13,809

Long-term debt (m)

- -

275

297

320

147

- -

2,696

1,980

2,701

2,702

Equity (m)

460

419

397

528

486

1,245

1,952

2,542

3,655

4,449

6,144

8,757

11,090

11,025

18,769

22,664

23,495

ROIC

- -

(12.7)%

(10.1)%

(9.7)%

(17.1)%

43.4%

17.0%

11.3%

13.4%

15.7%

15.9%

24.0%

16.9%

24.6%

37.8%

16.8%

14.5%

Return on capital

(11.3)%

(10.8)%

(9.4)%

(8.8)%

(15.2)%

22.1%

25.7%

21.0%

22.1%

19.2%

24.0%

22.0%

16.6%

22.5%

36.9%

16.8%

14.4%

Return on equity

(22.9)%

(19.7)%

(17.1)%

(19.8)%

(45.7)%

60.2%

21.7%

13.7%

17.4%

20.1%

19.5%

27.9%

19.1%

31.9%

43.0%

19.1%

17.8%

Plowback ratio

100.0%

- -

100.0%

Div.&Repurch./FCF

- -

(80.5)%

32.2%

34.5%

(7.0)%

1.7%

5.9%

4.3%

12.6%

197.3%

15.4%

- -

29.7%

38.3%

Capital Structure

4 May · 2023 | Q1

All numbers in millions

Total liabilities

$ 6,565

Total assets

$ 30,060

Long-term debt

$ 2,702

Cash and equiv.

$ 3,916

Goodwill

$ - -

Retained earnings

$ 24,125

Common stock

107

Enterprise Value

$ 81,081

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

3,587

5,695

7,742

Receivables

4,115

6,037

5,329

Inventory

1,917

1,951

1,880

Other

161

1,024

1,845

Current assets

9,779

14,015

15,884

Acc. Payable

476

564

589

Debt due

- -

720

Other

2,222

2,649

1,832

Current liabilities

2,697

3,933

3,141

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

(24.26)%

22.53%

24.80%

Cash flow

(8.27)%

43.63%

41.57%

Earnings

(46.28)%

34.05%

42.17%

Dividends

- -

Book value

20.75%

29.26%

32.60%

Insider Trading

Type

Date

Ryan Arthur F

Sale

06/01/23

Ryan Arthur F

Sale

06/01/23

Ryan Arthur F

Sale

06/01/23

Ryan Arthur F

Sale

06/01/23

Ryan Arthur F

Sale

06/01/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2021

2,529

5,139

3,453

4,952

16,072

2022

2,965

2,857

2,936

3,414

12,173

2023

3,162

- -

Earnings per share

Currency: USD

Year

Total

2021

10.36

28.80

15.17

20.72

75.05

2022

9.09

7.96

12.28

11.18

40.51

2023

7.64

- -

Quarterly dividends paid

Currency: USD

Year

Total

2021

- -

2022

- -

2023

- -

Company Description

Sector:

Healthcare

Industry:

Biotechnology

CEO:

Dr. Leonard S. Schleifer M.D., Ph.D.

Full-time employees:

12,099

City:

Tarrytown

Address:

777 Old Saw Mill River Road

IPO:

Jan 1, 1991

CIK:

0000872589

Website:

regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Powered by AI

Regeneron Pharmaceuticals, Inc.

750.12